Search
for
Sort by
Research 361–390 of 1000+
- Alopecia areata: Ritlecitinib generates substantial re-growth of scalp hair
- Risk of Periodontal Diseases in Women With Polycystic Ovary Syndrome: An Overview
- Risk factors and comorbidities associated with central centrifugal cicatricial alopecia
- Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
- An Expert System for Clinical Risk Assessment of Polycystic Ovary Syndrome under Uncertainty
- La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos
- Use of Platelet-Rich Plasma in the Management of Alopecia Areata
- 44047 Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
- Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- Risk Factors Affecting Khalitya (Hair Fall) As Per Deha Prakruti- A Case Control Study Among Adults
- From diagnosis to recovery: A practical approach to ringworm treatment in cattle
- 598 Response to ritlecitinib treatment based on salt improvement scores in patients with alopecia areata (AA): Post hoc analysis of the allegro phase 2b/3 study
- Data from Ribonucleotide Excision Repair Is Essential to Prevent Squamous Cell Carcinoma of the Skin
- Data from Ribonucleotide Excision Repair Is Essential to Prevent Squamous Cell Carcinoma of the Skin
- Physical and Chemical Properties of Selected Sample of Castor Oil, Ricinus communis L.
- Sustained hair regrowth with ritlecitinib to Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
- Vitamin D dependent rickets type 2: a case-based review of patient with alopecia and rickets
- A RARE CASE OF VITAMIN D DEPENDENT RICKETS TYPE-2A PRESENTED AS ALOPECIA TOTALIS
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Risk of ovarian hyperstimulation syndrome in infertile patients with PCOS treated by HP HMG
- The utilisation of cardiac risk ratio and non-HDL cholesterol markers to assess cardiovascular risk in type 2 diabetes males with lowered serum DHT
- Formulation and Evaluation of Herbal Shampoo from Fermented Rice Water and its Anti-Fungal Activity
- Cat Contact as A Risk Factor for Tinea Capitis Infection
- Progression of Pseudolymphoma to true Cutaneous lymphoma, possible role of Platelet-rich plasma (PRP), a case report.
- USE OF RICE WATER (Oryza Sativa) & HIBISCUS (Hibiscus Rosa- sinensis)
- Risks of Protein Conditioner Application under the Impact of Heat and/or Gamma Irradiation in Albino Rats
- Risk of autoimmune diseases in patients with RASopathies: systematic study of humoral and cellular immunity
- Ringworm in dogs
- Risk Factors and Prognosis of Folliculitis at Recipient Sites Following Hair Restoration Surgery
- EP06 Successful treatment of alopecia universalis with rituximab therapy